Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07462403 · ClinicalTrials.gov registry record · NA

A mLifestyle Intervention for Men on Androgen Deprivation Therapy for PCa

A NA study of Prostate Cancer, sponsored by Thomas Jefferson University.

Active
Registry status
NA
Development phase
45
Enrollment target
1
Study location

NCT07462403: Active NA study of Prostate Cancer, sponsored by Thomas Jefferson University.

NCT07462403 is a NA study of Prostate Cancer that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 45 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT07462403, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by Thomas Jefferson University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

Participants in the study will have weekly phone calls with a trained health coach. During these calls, they will receive guidance on extending their overnight fasting time-starting with at least 12 hours and slowly working toward 16 hours each night. Participants will also use a text-message system to report when they start and stop fasting and to share information about their sleep. The system will send encouraging messages when they meet their fasting goals, along with tips and helpful reminders. Healthy Eating Attention Control Group: Participants in this group will receive two text messages each day with simple, evidence-based information and tips on healthy eating. These messages are based on materials from the American Institute for Cancer Research (AICR).

Primary Outcome

Percentage of eligible participants who consent and enroll in the study.

Conditions Studied

Interventions

  • BEHAVIORAL mLifestyle
  • BEHAVIORAL Healthy Diet Text Messaging

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2024-05-02
Est. Completion 2026-12-31
Phase NA
Thomas Jefferson University

292 total trials

What the registry record for NCT07462403 still lists

NCT07462403 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which mLifestyle is the first listed.

NCT07462403 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07462403 about?

NCT07462403 is a clinical study titled "A mLifestyle Intervention for Men on Androgen Deprivation Therapy for PCa". Participants in the study will have weekly phone calls with a trained health coach. During these calls, they will receive guidance on extending their overnight fasting time-starting with at least 12 hours and slowly working toward 16 hours each night. Participants will also use a text-message system...

What is the current status of trial NCT07462403?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2024-05-02. Estimated completion is 2026-12-31.

What conditions does trial NCT07462403 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT07462403?

The interventions under investigation include: mLifestyle (BEHAVIORAL), Healthy Diet Text Messaging (BEHAVIORAL).

Who is sponsoring clinical trial NCT07462403?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07462403 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07462403's enrollment target sits among peer trials

45 506th of 735 higher than 223 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07462403, the US trial registry maintained by the National Library of Medicine. NCT07462403 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.